OSUR ORASURE TECHNOLOGIES INC

Nasdaq orasure.com


$ 2.72 $ 0.03 (1.12 %)    

Friday, 31-Oct-2025 15:29:10 EDT
QQQ $ 631.49 $ -2.52 (-0.4 %)
DIA $ 476.57 $ 0.68 (0.14 %)
SPY $ 684.14 $ -0.93 (-0.14 %)
TLT $ 90.29 $ -0.27 (-0.3 %)
GLD $ 368.01 $ -2.46 (-0.66 %)
$ 2.7
$ 2.70
$ 2.72 x 947
$ 2.73 x 990
$ 2.68 - $ 2.74
$ 2.36 - $ 4.60
381,284
na
197.47M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-07-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-03-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-14-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 orasure-technologies-mara-g-aspinall-resigns-john-p-kenny-appointed-as-chair

-SEC Filing

Core News & Articles

Orasure stock price has dropped 11% in 4 weeks, 32% in 12 monthsZwanziger offered $3.50-$4 a share, price now under $3/shareOra...

 orasure-technologies-sees-q3-sales-27000m-30000m-vs-3315m-est

OraSure Technologies (NASDAQ:OSUR) sees Q3 sales of $27.000 million-$30.000 million vs $33.15 million analyst estimate.

 orasure-technologies-q2-adj-eps-019-beats-020-estimate-sales-3124m-beat-3052m-estimate

OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of ...

 orasure-technologies-files-for-mixed-shelf-of-up-to-300m

- SEC Filing

 evercore-isi-group-maintains-in-line-on-orasure-technologies-maintains-3-price-target

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:OSUR) with a In-Line and maintains $3 price ta...

 orasure-technologies-sees-q2-sales-28500m-32500m-vs-3296m-est

OraSure Technologies (NASDAQ:OSUR) sees Q2 sales of $28.500 million-$32.500 million vs $32.96 million analyst estimate.

 orasure-technologies-q1-adj-eps-018-beats-020-estimate-sales-2993m-beat-2918m-estimate

OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...

 orasure-technologies-sees-q1-sales-27500m-31500m-vs-3238m-est

OraSure Technologies (NASDAQ:OSUR) sees Q1 sales of $27.500 million-$31.500 million vs $32.38 million analyst estimate.

 orasure-technologies-q4-adj-006-inline-sales-3745m-beat-3672m-estimate

OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. Thi...

 oraquick-hiv-self-test-gains-approval-for-adolescents-expanding-access-to-hiv-testing-for-ages-14-and-up

The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Pre...

 orasure-technologies-acquires-sherlock-biosciences-no-financial-terms-disclosed

OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample manage...

 orasure-secures-75m-contract-with-11m-potential-for-marburg-virus-rapid-test-development

OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, ...

 orasure-technologies-q3-2024-adj-eps-001-beats-008-estimate-sales-39915m-beat-39019m-estimate

OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION